Ari-0001

Leukemia, B-Cell

jiuwei cuiCell therapyPhase 1Dormant

CC

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 89/ 100

Competitive context

2 Active assets in the Leukemia, B-Cell cohort.

Asset / Sponsor	Phase	Rating
DEXAMETHASONE St. Jude Children's Research Hospital	Phase 2	BB
PREDNISONE TABLETS Children's Oncology Group	Phase 2	B
Cyclophosphamide Dana-Farber Cancer Institute	Phase 2	B
Inno-206 Children's Oncology Group	Phase 2	B
Solu-Cortef Children's Oncology Group	Phase 2	B

View all 22 →

Same molecule, other indications

Ari-0001 is also rated in:

diffuse large B-cell lymphomaDormant

B

Indicative ·

62 / 100

Acute Lymphoblastic Leukemia ,LymphomasDormant

B

Indicative ·

60 / 100

Primary Mediastinal B-cell Lymphoma (PMBCL)Dormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.